GlassScriptPhysician profile
Erin Stockwell
NPI 1467838599
$15,090.40
in general payments reported to CMS, 2019-2025
32 companies · $6,057 in 2025
The $6,057 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $682 · 2022: $2,122 · 2023: $4,312 · 2024: $1,916 · 2025: $6,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,324 · Food and Beverage: $4,989 · Consulting Fee: $919 · Education: $54.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,324.28 |
| Food and Beverage | $4,989.02 |
| Consulting Fee | $918.75 |
| Education | $54.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,202.53 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Boston Scientific Corporation | $3,308.82 | 2021-2025 | General - Therapies, Wavewriter Alpha Prime 16, General - Pain Management |
| Saluda Medical Americas, INC. | $2,517.04 | 2024-2025 | Evoke |
| Vertos Medical, INC. | $1,015.12 | 2022-2024 | Mild Device Kit |
| Nalu Medical, INC. | $707.02 | 2022-2025 | Nalu Neurostimulation System |
| Abbott Laboratories | $689.62 | 2021-2024 | Eterna, Proclaim |
| Collegium Pharmaceutical, INC. | $260.52 | 2021-2025 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $260.33 | 2021-2025 | Ztlido |
| Abbvie INC. | $158.36 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $121.08 | 2022 | |
| Relievant Medsystems, INC. | $72.15 | 2023 | Intracept |
| Arbor Pharmaceuticals, INC. | $65.15 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $58.34 | 2023 | Horizant |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.89 | 2021-2022 | |
| Grt US Holding, INC. | $57.84 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $57.52 | 2021 | |
| Tersera Therapeutics LLC | $55.51 | 2021-2022 | |
| Avanos Medical | $52.47 | 2024 | Coolief* Cooled Radiofrequency |
| Pfizer INC. | $47.67 | 2021-2024 | |
| Almatica Pharma LLC | $44.42 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $42.01 | 2021-2022 | |
| Allergan, INC. | $38.99 | 2022 | |
| Redhill Biopharma INC. | $32.68 | 2021 | |
| Mml US, INC. | $27.31 | 2023-2025 | Reactiv8 |
| Fidia Pharma USA INC. | $26.63 | 2023 | Hymovis, Triluron |
| Horizon Therapeutics Plc | $24.91 | 2021 | |
| Protega Pharmaceutials INC | $19.17 | 2022 | |
| Nevro Corp. | $19.00 | 2022 | |
| Biotronik Nro, INC. | $16.70 | 2025 | Prospera |
| Ipsen Biopharmaceuticals, INC | $14.59 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.99 | 2021 | |
| Stimwave Technologies Incorporated | $7.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Stockwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.